Goldman Sachs
BIOA

Goldman Sachs’s BioAge Labs BIOA Stock Holding History

Goldman Sachs’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74M Buy
156,438
+30,200
+24% +$582K ﹤0.01% 4251
2025
Q4 		$1.67M Buy
126,238
+36,560
+41% +$324K ﹤0.01% 4750
2025
Q3 		$527K Buy
89,678
+64,886
+262% +$304K ﹤0.01% 5480
2025
Q2 		$102K Sell
24,792
-1,967
-7% -$7.92K ﹤0.01% 5810
2025
Q1 		$101K Sell
26,759
-169,208
-86% -$782K ﹤0.01% 5784
2024
Q4 		$1.13M Buy
195,967
+87,351
+80% +$1.51M ﹤0.01% 4735
2024
Q3 		$2.26M Buy
+108,616
New +$2.18M ﹤0.01% 4055

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Goldman Sachs's BIOA Position: Q1 2026 in Review

Goldman Sachs increased its BioAge Labs (BIOA) stake by 24% in Q1 2026, buying an estimated $582K and bringing the position to 156,438 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #4251.

Goldman Sachs first reported a position in BIOA in Q3 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Goldman Sachs held 156,438 shares of BioAge Labs worth $2.74M as of Q1 2026.
  • Goldman Sachs bought 30,200 BioAge Labs shares in Q1 2026, an estimated $582K.
  • BioAge Labs made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4251 holding.
  • Goldman Sachs first reported a position in BioAge Labs in Q3 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.